American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial. [electronic resource]
Producer: 20110204Description: 128-34 p. digitalISSN:- 2151-4658
- Adult
- Antibodies, Monoclonal, Humanized
- Arthritis, Rheumatoid -- drug therapy
- Certolizumab Pegol
- Drug Therapy, Combination
- Female
- Humans
- Immunoglobulin Fab Fragments -- administration & dosage
- Male
- Methotrexate -- administration & dosage
- Polyethylene Glycols -- administration & dosage
- Rheumatology -- standards
- Societies, Medical -- standards
- United States
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.